Therma Bright (TSE:THRM) has released an update.
Therma Bright Inc. is on the brink of receiving CMS approval for permanent coding of its Venowave VW5 device, which could benefit many U.S. citizens affected by various venous conditions. This anticipated approval could catalyze the company’s market presence and enhance shareholder value, considering the significant market potential for deep vein thrombosis treatments.
For further insights into TSE:THRM stock, check out TipRanks’ Stock Analysis page.
